Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 1/20 | 0.60 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.60 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.57 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.55 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | BCHE | P06276 | 2/20 | 0.54 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.53 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2574407 | 0.87 | MRGPRX4 (0.60) | MRGPRX4SMPD1HDAC4NR4A2BCHE | |
| SCHEMBL2749630 | 0.87 | CYP4F2 (0.63) | LTA4HPLA2G2ASMPD1FFAR1NR4A2 | |
| SCHEMBL2567827 | 0.85 | LTA4H (0.51) | LTA4HPLA2G2AMRGPRX4SMPD1HDAC4 | |
| SCHEMBL1437584 | 0.84 | FFAR1 (0.65) | LTA4HFFAR1FFAR4NR4A2BCHE | |
| SCHEMBL8339114 | 0.83 | FFAR1 (0.78) | MRGPRX4FFAR1AKR1B1FFAR4 | |
| SCHEMBL12646542 | 0.81 | FFAR1 (0.60) | MRGPRX4SMPD1HDAC4FFAR1AKR1B1 | |
| SCHEMBL7445953 | 0.81 | CYP4F2 (0.72) | LTA4HMRGPRX4SMPD1HDAC4FFAR1 | |
| SCHEMBL1728418 | 0.81 | CNR1 (0.59) | FFAR1HTT | |
| SCHEMBL3278183 | 0.80 | HCAR2 (0.54) | KDM4E | |
| SCHEMBL2137838 | 0.79 | MRGPRX4 (0.69) | MRGPRX4HDAC4NR4A2BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1813623-B1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | KISSEI PHARMACEUTICAL (JP) | 2011-11-09 | — | — | EP | disclosed |
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7795236-B2 | Purine nucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1813623-A1 | PURINENUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICINAL USE THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2007-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249054-A9 | PURINE NUCLEOSIDE DERIVATIVE MODIFIED IN 8-POSITION AND MEDICAL USE THEREOF | NUDT1, PNP, SLC28A2 | LTA4H 1776/4885PLA2G2A 3195/4885MRGPRX4 1757/4885 |
| US-20070179115-A1 | Purinenucleoside derivative modified in 8-position and medical use thereof | NUDT1, SLC28A2, PNP | LTA4H 1619/4885PLA2G2A 3081/4885MRGPRX4 1683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.